US biotech Arbutus Biopharma (Nasdaq: ABUS) has reacquired the rights to its lead hepatitis B candidate, imdusiran (AB-729), ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for ...

Mabwell’s subsidiary T-mab enters into an agreement with Qilu Pharma for Albipagrastim alfa for injection: Shanghai Monday, June 30, 2025, 15:00 Hrs [IST] Mabwell, an innovative ...

Qilu currently has 12 subsidiaries, 11 domestic manufacturing sites and over 36,000 employees worldwide. Qilu ranks among Top 3 in Chinese pharmaceutical industry in 2024.

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan ...

BEIJING -- The National Natural Science Foundation of China (NSFC) on Monday launched the Private Enterprise Innovation and ...

Arbutus Biopharma had made no secret of its plans to step up its work on imdusiran. | Arbutus had made no secret of its desire to step up its plans for imdusiran. Now, the company has regained the ...

Company News Published 06/25/2025, 07:41 AM 0 Arbutus reacquires China rights to imdusiran after Qilu partnership ends ABUS -1.28% ...